全文获取类型
收费全文 | 9543篇 |
免费 | 749篇 |
国内免费 | 21篇 |
专业分类
耳鼻咽喉 | 107篇 |
儿科学 | 313篇 |
妇产科学 | 277篇 |
基础医学 | 1139篇 |
口腔科学 | 87篇 |
临床医学 | 1159篇 |
内科学 | 1664篇 |
皮肤病学 | 120篇 |
神经病学 | 938篇 |
特种医学 | 239篇 |
外科学 | 1255篇 |
综合类 | 100篇 |
一般理论 | 3篇 |
预防医学 | 1277篇 |
眼科学 | 239篇 |
药学 | 681篇 |
中国医学 | 5篇 |
肿瘤学 | 710篇 |
出版年
2023年 | 80篇 |
2022年 | 152篇 |
2021年 | 285篇 |
2020年 | 183篇 |
2019年 | 214篇 |
2018年 | 283篇 |
2017年 | 227篇 |
2016年 | 216篇 |
2015年 | 255篇 |
2014年 | 351篇 |
2013年 | 514篇 |
2012年 | 702篇 |
2011年 | 751篇 |
2010年 | 431篇 |
2009年 | 369篇 |
2008年 | 572篇 |
2007年 | 552篇 |
2006年 | 506篇 |
2005年 | 557篇 |
2004年 | 489篇 |
2003年 | 433篇 |
2002年 | 396篇 |
2001年 | 124篇 |
2000年 | 119篇 |
1999年 | 113篇 |
1998年 | 74篇 |
1997年 | 71篇 |
1996年 | 51篇 |
1995年 | 47篇 |
1994年 | 33篇 |
1993年 | 26篇 |
1992年 | 76篇 |
1991年 | 89篇 |
1990年 | 77篇 |
1989年 | 62篇 |
1988年 | 85篇 |
1987年 | 68篇 |
1986年 | 79篇 |
1985年 | 75篇 |
1984年 | 50篇 |
1983年 | 45篇 |
1982年 | 32篇 |
1981年 | 34篇 |
1980年 | 28篇 |
1979年 | 39篇 |
1978年 | 30篇 |
1977年 | 27篇 |
1976年 | 31篇 |
1975年 | 24篇 |
1974年 | 34篇 |
排序方式: 共有10000条查询结果,搜索用时 15 毫秒
1.
Hommes Franziska Mohsenpour Amir Kropff Dana Pilgram Lisa Matusall Svenja von Philipsborn Peter Sell Kerstin 《Bundesgesundheitsblatt, Gesundheitsforschung, Gesundheitsschutz》2022,65(1):96-106
Bundesgesundheitsblatt - Gesundheitsforschung - Gesundheitsschutz - Akteure der öffentlichen Gesundheit (Public Health) tragen wesentlich zu Gesundheitsschutz, -förderung und... 相似文献
2.
Dana Franzen-Klein Mark Jankowski Charlotte L. Roy Hoa Nguyen-Phuc Da Chen Lorin Neuman-Lee 《Journal of toxicology and environmental health. Part A》2020,83(2):45-65
ABSTRACTDomestic chickens (Gallus gallus domesticus) were exposed to imidacloprid by gavage once daily for 7 consecutive days at 0, 0.03, 0.34, 3.42, 10.25, and 15.5 mg/kg/day (n = 20 per group; 5 6-week-old males, 5 6-week-old females, 5 9-week-old males, and 5 9-week-old females). The severity and duration of neurobehavioral abnormalities were recorded. Components of the innate and adaptive immune system were assessed with 7 standard functional assays. Temporary neurobehavioral abnormalities were observed in a dose-dependent manner, including muscle tremors, ataxia, and depressed mentation. Based upon mean clinical severity scores, the no observed adverse effect level (NOAEL) was 3.42 mg/kg/day, and the lowest observed adverse effect level (LOAEL) was 10.25 mg/kg/day. The effective dose value for the presence of any neurobehavioral abnormalities in 50% of the test group (ED50) was 4.62 ± 0.98 mg/kg/day. The ED50 for an adjusted score that included both severity and duration of neurobehavioral abnormalities was 11.24 ± 9.33 mg/kg/day. These ED50 values are equivalent to a 1 kg bird ingesting 29 or 70 imidacloprid treated soybean seeds respectively. Immunotoxicity was not documented, possible causes include the assays were insensitive, relevant immune functions were not examined, or imidacloprid is not immunotoxic at this dosing schedule in this species. Neurobehavioral abnormalities were a more sensitive indicator of the sublethal effects of imidacloprid than immunotoxicity. 相似文献
3.
4.
Mhd Wasem Alsabbagh Dana Church Lisa Wenger John Papastergiou Lalitha Raman-Wilms Eric Schneider Nancy Waite 《Research in social & administrative pharmacy》2019,15(2):202-206
Background
One approach to boost influenza vaccination coverage has been to expand immunization authority. In 2012, the province of Ontario gave community pharmacists the authority to administer the influenza vaccine.Objective
This study investigates the perspectives of Ontario pharmacy patrons, who had not recently received this vaccine from a pharmacist, regarding this pharmacist service.Methods
A survey was administered in six Ontario community pharmacies to pharmacy patrons who had not received an influenza vaccination from a pharmacist during the previous year. The instrument included questions about influenza vaccination, and knowledge of and attitudes toward vaccines and pharmacist-administered immunization.Results
A total of 541 pharmacy patrons completed the survey (53.9% response rate). About one-third (30.5%) of respondents were not aware that pharmacists could give the influenza vaccine, with younger individuals being less likely to be aware (OR 0.48, 95% CI 0.29–0.77, p?<?0.05) and less likely to receive the vaccine annually (OR 0.28, 95% CI 0.19–0.42, p?<?0.05). Leading reasons respondents gave as to why they did not receive their influenza vaccine from a pharmacist included not wanting or feeling they needed to be immunized (41.6%) and being used to receiving the vaccine from a physician (16.5%). Concerns about the experience and training of pharmacists and lack of privacy in a community pharmacy were uncommon.Conclusion
Reduced awareness of the availability of pharmacist-provided influenza vaccine is still common. Pharmacists have a significant opportunity to address lack of awareness and vaccine hesitancy issues. They can promote this service to increase influenza vaccination rates among pharmacy patrons who do not utilize this professional service. 相似文献5.
6.
7.
8.
9.
Practical management of patients with non-small-cell lung cancer treated with gefitinib. 总被引:7,自引:0,他引:7
Neelam T Shah Mark G Kris William Pao Leslie B Tyson Barbara M Pizzo Murk-Hein Heinemann Leah Ben-Porat Dana L Sachs Robert T Heelan Vincent A Miller 《Journal of clinical oncology》2005,23(1):165-174
PURPOSE: The use of gefitinib, the first drug approved to inhibit the epidermal growth factor receptor tyrosine kinase, is indicated in patients with non-small-cell lung cancer with tumors progressive after chemotherapy. The unique mechanism of action of this agent leads to distinctive patterns of response and toxicity in persons with lung cancer. Many of the principles of management relevant to gefitinib are distinct from those with conventional cytotoxic drugs. To meet this need, we present practical guidelines on the use of gefitinib in patients with non-small-cell lung cancer. METHODS: This article reviews gefitinib's indications, dosing, response phenomena, and patterns of relapse in individuals with radiographic response. RESULTS: We present our recommendations for the management of rash and diarrhea caused by this agent. CONCLUSION: This information can guide practitioners and help them inform their patients about what to expect when they receive gefitinib. 相似文献
10.